Abstract: 【Abstract】Objective To evaluate the safety and efficacy of argatroban and low-molecular-weight heparin (LMWH) in hemodialysis. Method PubMed, EMBASE, Cochrane library, CNKI, and Wanfang were searched for randomized controlled trials for argatroban and LMWH in hemodialysis. RevMan5.3 was used to perform statistical analyses. Result A total of 6 studies were enrolled, including 467 patients (236 in argatroban group, 231 in LMWH group). Meta analysis showed that argatroban group and LMWH group had no significant differences in clotting events in extracorporeal circuit during hemodialysis (RR=0.740, 95% CI0.470～1.150, P=0.180); platelet counts were significantly higher in argatroban group than in LMWH group (MD=20.000, 95% CI 10.120～29.870, P＜0.001), bleeding rate during hemodialysis was significantly lower in argatroban group than in LMWH group (RR=0.220, 95% CI 0.070～0.680, P=0.009); and the ligature time for puncture site was significantly shorter in argatroban group than in LMWH group (MD=-1.350, 95% CI -1.850～-0.840, P＜0.001). Conclusion The ratio of clotting events in extracorporeal circuit during hemodialysis was similar between argatroban group and LMWH group. Argatroban seems safer than LMWH in less influence on PLT, lower bleeding rate and shorter ligature time for puncture site.

Key words: argatroban, low-molecular-weight heparin, hemodialysis, meta-analysis